Search results for " Humans"

showing 10 items of 2466 documents

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era. Selecting cases, matching clinical bene…

2019

An accurate diagnosis of clinically distinct subgroups of aggressive mature B cell lymphomas is crucial for the choice of proper treatment. Presently, precise recognition of these disorders relies on the combination of morphological, immunophenotypical, and cytogenetic/molecular features. The diagnostic workup in such situations implies the application of costly and time-consuming analyses, which are not always required, since an intensified treatment option is reasonably reserved to fit patients. The Italian Group of Haematopathology proposes herein a practical algorithm for the diagnosis of aggressive mature B cell lymphomas based on a stepwise approach, aimed to select cases deserving mo…

0301 basic medicinemedicine.medical_specialtyMatching (statistics)Lymphoma B-CellLymphomadouble hitComputer scienceMYCDouble hitFluorescencePathology and Forensic MedicineImmunophenotyping03 medical and health sciences0302 clinical medicineFISHDiagnosismedicinePractical algorithmHumansIntensive care medicineB-cell lymphomaMolecular BiologyIn Situ HybridizationIn Situ Hybridization FluorescenceHGBLBrief ReportB-CellTreatment optionsCorrectionDiagnosis; DLBCL; Double hit; FISH; HGBL; MYC; Humans; Immunophenotyping; In Situ Hybridization Fluorescence; Lymphoma B-Cell; AlgorithmsCell BiologyGeneral MedicineDiagnosis DLBCL Double hit FISH HGBL MYCmedicine.diseaseDiagnosis; DLBCL; double hit; FISH; HGBL; MYCOptimal managementMolecular analysis030104 developmental biology030220 oncology & carcinogenesisDLBCLPosition paperProper treatmentAlgorithmsDiagnosiHuman
researchProduct

A case of infective colitis due to Yersinia enterocolitica complicated by microliver abscesses mimicking multiple liver occult metastases: a case rep…

2021

Abstract Background We report an unusual case of infective colitis by Yersinia enterocolitica complicated by microliver abscesses mimicking multiple liver metastases in a 79 yr old female without any risk factors for bacteriaemia by this pathogen. Case presentation The patient was admitted to the Internal Medicine with Stroke Care ward of University Policlinico “P. Giaccone” in Palermo because of the appearance of diarrhoea. After the antimicrobial treatment for infective colitis, the clinicians observed a persistently increased white blood cells (WBC) count and multiple hepatic lesions; after having excluded any neoplastic disease and inflammatory bowel disease (IBD), blood cultures positi…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaCase report Infective colitis Microliver abscesses Yersinia enterocolitica Aged Anti-Bacterial Agents Bacteremia Liver Neoplasms Treatment Outcome Yersinia Infections Colitis Diagnosis Differential Female Humans Liver AbscessYersinia Infections030106 microbiologyLiver AbscessInfective colitisCase ReportBacteremiaInfectious and parasitic diseasesRC109-216Inflammatory bowel diseaseGastroenterologyMetastasisDiagnosis Differential03 medical and health sciences0302 clinical medicineMedical microbiologyInternal medicinemedicineHumans030212 general & internal medicineYersinia enterocoliticaYersinia enterocoliticaAgedDoxycyclinebiologybusiness.industryLiver NeoplasmsMicroliver abscessesmedicine.diseasebiology.organism_classificationColitisOccultAnti-Bacterial AgentsInfectious DiseasesTreatment OutcomeFemaleDifferential diagnosisbusinessCefiximemedicine.drugBMC Infectious Diseases
researchProduct

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

2020

For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differe…

0301 basic medicinemedicine.medical_specialtyanti-MAG polyneuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; sensitivity; specificity; autoantibodies; case-control studies; enzyme-linked immunosorbent assay; humans; myelin-associated glycoprotein; polyneuropathies; retrospective studiesImmunologyAnti-MAG polyneuropathyEnzyme-Linked Immunosorbent AssaySettore MED/26GastroenterologyPolyneuropathies03 medical and health sciencesSensitivity0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyIn patientAutoantibodiesRetrospective Studieschronic inflammatory demyelinating polyradiculoneuropathyAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathybiologybusiness.industryAnti magAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; Sensitivity; Specificitymedicine.diseaseAutoantibodieMyelin-Associated GlycoproteinTiter030104 developmental biologyPolyneuropathienervous systemNeurologyCase-Control StudiesElisa testSpecificitybiology.proteinELISANeurology (clinical)AntibodyCase-Control StudiebusinessSensitivity (electronics)Polyneuropathy030217 neurology & neurosurgeryHumanJournal of Neuroimmunology
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society …

2021

Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their managem…

0301 basic medicinemedicine.medical_treatmentSleep disorders.Comorbidity0302 clinical medicineCardiovascular DiseaseSleep Initiation and Maintenance DisordersInsomniaContinuous positive airway pressureSleep Apnea ObstructiveContinuous Positive Airway Pressureblood pressureHeart Disease Risk FactorPrognosisSleep in non-human animalsCircadian RhythmAntihypertensive AgentCardiovascular Diseasessleep disordersmedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentHumancardiovascular riskmedicine.medical_specialtyConsensusSleep ApneahypertensionPrognosiConsensuRisk Assessment03 medical and health sciencesTherapeutic approachInternal MedicinemedicineHumansHealthy LifestyleIntensive care medicineConsensus DocumentAntihypertensive AgentsBlood pressure; Cardiovascular risk; Hypertension; Sleep disorders; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Comorbidity; Consensus; Healthy Lifestyle; Heart Disease Risk Factors; Humans; Hypertension; Prognosis; Risk Assessment; Risk Reduction Behavior; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Continuous Positive Airway Pressure; SleepSleep disorderbusiness.industryObstructivePublic healthmedicine.diseaseComorbidity030104 developmental biologyBlood pressureHeart Disease Risk Factorsblood pressure; cardiovascular risk; hypertension; sleep disordersbusinessSleepRisk Reduction Behavior030217 neurology & neurosurgery
researchProduct

Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of…

2020

ObjectiveTo assess the predictive role of ferritin and C-reactive protein (CRP) on occurrence of macrophage activation syndrome (MAS) and mortality in patients with adult onset Still's disease (AOSD), a rare and severe disease, included in the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort.MethodsThe predictive role, at the time of diagnosis, of serum levels of ferritin and CRP on occurrence of MAS and mortality, was evaluated by logistic regression analyses and receiver-operating characteristic (ROC) curves were built to identify patients at high risk of MAS and mortality, respectively.ResultsIn assessed 147 patients with AOSD, levels of ferri…

0301 basic medicinemyalgiaAdult-OnsetMalePredictive Value of TestPathology and Laboratory MedicineLogistic regressionBiochemistryGastroenterologyCohort StudiesMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesMultidisciplinarybiologyMacrophage Activation SyndromeStatisticsQRMiddle AgedC-Reactive ProteinsC-Reactive ProteinPredictive value of testsPhysical SciencesCohortRegression AnalysisMedicineFemalemedicine.symptomStill's Disease Adult-OnsetResearch ArticleCohort studyHumanAdultmedicine.medical_specialtyPatientsLogistic ModelInflammatory DiseasesSciencePainStill's Disease Adult-Onset.Research and Analysis Methods03 medical and health sciencesAdult; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Ferritins; Humans; Logistic Models; Macrophage Activation Syndrome; Male; Middle Aged; Predictive Value of Tests; ROC Curve; Still's Disease Adult-OnsetSigns and SymptomsDiagnostic MedicinePredictive Value of TestsInternal medicinemedicineHumansStatistical Methods030203 arthritis & rheumatologyFerritinbusiness.industryC-reactive proteinBiology and Life SciencesProteinsProtein ComplexesMyalgiaBiomarkermedicine.diseaseStill's DiseaseHealth CareFerritin030104 developmental biologyLogistic ModelsROC CurveMacrophage activation syndromeMultivariate AnalysisFerritinsbiology.proteinCohort StudiebusinessMathematicsBiomarkers
researchProduct

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with differe…

2016

OBJECTIVES: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. METHODS: NS3 protease sequencing was performed by in-house-developed HCV-1 subtype-specific protocols. Phylogenetic analysis was used to test sequencing reliability and concordance with previous genotype/subtype assignment by commercial genotyping assays. RESULTS: Five hundred and sixty-seven HCV plasma samples with quantifiable HCV-RNA from 326 HCV-infected patients were collected between 2011 and 2014. Overall, the success rate of NS3 sequencing was 88.9%. The success rate between the two subtype…

0301 basic medicinens3Genotyping TechniquesvirusesDrug ResistanceHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyTelaprevirchemistry.chemical_compoundgenotype; genotyping techniques; hepacivirus; hepatitis C; humans; RNA viral; retrospective studies; sequence analysis; DNA; viral nonstructural proteins; drug resistance viral; mutation; pharmacology; infectious diseases0302 clinical medicineRetrospective StudieGenotypePharmacology (medical)ViralGenotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; RNA Viral; Retrospective Studies; Sequence Analysis DNA; Viral Nonstructural Proteins; Drug Resistance Viral; MutationProteolytic enzymesvirus diseasesSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis Chcv-rna levelsInfectious DiseasesHCV-RNARNA Viral030211 gastroenterology & hepatologySequence Analysismedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyGenotypeHepatitis C virusConcordanceSettore MED/12 - GASTROENTEROLOGIAGenotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; RNA Viral; Retrospective Studies; Sequence Analysis DNA; Viral Nonstructural Proteins; Drug Resistance Viral; Mutation; Pharmacology; Pharmacology (medical); Infectious DiseasesBiology03 medical and health sciencesBoceprevirInternal medicineDrug Resistance ViralmedicinehcvHumansGenotypingGenotyping TechniquesRetrospective StudiesPharmacologyHepaciviruViral Nonstructural ProteinSettore MED/09 - MEDICINA INTERNASequence Analysis DNADNAVirologydigestive system diseases030104 developmental biologychemistrySequence AnalysiMutationRNAGenotyping TechniqueRNA viral
researchProduct